Fluoguide AS
STO:FLUO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.9
75.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Cash & Cash Equivalents
Fluoguide AS
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
Cash & Cash Equivalents
kr21.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
226%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Cash & Cash Equivalents
kr4.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
49%
|
CAGR 10-Years
27%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash & Cash Equivalents
kr511m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
5%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash & Cash Equivalents
€625.5m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
55%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash & Cash Equivalents
kr816.4m
|
CAGR 3-Years
64%
|
CAGR 5-Years
48%
|
CAGR 10-Years
22%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash & Cash Equivalents
kr103.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Cash & Cash Equivalents?
Cash & Cash Equivalents
21.7m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Cash & Cash Equivalents amounts to 21.7m DKK.
What is Fluoguide AS's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
226%
Over the last year, the Cash & Cash Equivalents growth was -17%. The average annual Cash & Cash Equivalents growth rates for Fluoguide AS have been 27% over the past three years , 226% over the past five years .
You don't have any saved screeners yet
